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Background: Cardiac pathological hypertrophy is associated with a significantly increased risk of coronary heart
disease and has been observed in diabetic patients treated with rosiglitazone whereas most published studies do
not suggest a similar increase in risk of cardiovascular events in pioglitazone-treated diabetic subjects. This study
sought to understand the pathophysiological and molecular mechanisms underlying the disparate cardiovascular
effects of rosiglitazone and pioglitazone and yield knowledge as to the causative nature of rosiglitazone-associated
cardiac hypertrophy.
Methods: We used a high-fat diet-induced pre-diabetic mouse model to allow bioinformatics analysis of the
transcriptome of the heart of mice treated with rosiglitazone or pioglitazone.
Results: Our data show that rosiglitazone and pioglitazone both markedly improved systemic markers for glucose
homeostasis, fasting plasma glucose and insulin, and the urinary excretion of albumin. Only rosiglitazone, but not
pioglitazone, tended to increase atherosclerosis and induced pathological cardiac hypertrophy, based on a significant
increase in heart weight and increased expression of the validated markers, ANP and BNP. Functional enrichment
analysis of the rosiglitazone-specific cardiac gene expression suggests that a shift in cardiac energy metabolism, in
particular decreased fatty acid oxidation toward increased glucose utilization as indicated by down regulation of
relevant PPARα and PGC1α target genes. This underlies the rosiglitazone-associated pathological hypertrophic cardiac
phenotype in the current study.
Conclusion: Application of a systems biology approach uncovered a shift in energy metabolism by rosiglitazone that
may impact cardiac pathological hypertrophy.Background
Type 2 diabetes mellitus (T2DM) is a strong independ-
ent risk factor for premature death and disability from
heart failure [1]. Managing T2DM and related heart
failure is an ongoing concern and adequate treatment
of T2DM remains an important issue. Thiazolidine-
diones (TZDs) are a class of drugs that initially showed
great promise as oral therapy for T2DM. The TZDs,* Correspondence: Lars.Verschuren@tno.nl
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hypoglycemic drugs in patients with T2DM, but due to
a relatively high risk of adverse cardiac effects, specific-
ally the use of rosiglitazone was banned in Europe in
2010 [2], whereas its use is restricted by the US Food
and Drug Administration [3].
Despite their chemical and mechanistic similarities,
there are large cohort studies suggesting that rosiglita-
zone causes heart failure to a greater extent than pioglit-
azone, yet provides no additional therapeutic benefit
[2,4,5]. Questions as to how rosiglitazone may be leading
to a relatively higher cardiovascular risk still remaintral Ltd. This is an Open Access article distributed under the terms of the
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nisms underlying the disparate cardiovascular effects of
rosiglitazone and pioglitazone may have translational im-
plications and yield knowledge as to the causative nature
of TZD-associated cardiac events in man [6].
Rosiglitazone and pioglitazone are thought to exert
their primary therapeutic effects through binding to the
peroxisome proliferator-activated receptor gamma (PPARγ),
thereby increasing sensitivity to insulin and producing
better glycemic control [7]. Although PPARγ is most
abundantly expressed in adipose tissue, it is widely
expressed throughout the body [8], including the liver,
skeletal muscle and, to a lesser extent, in the heart.
There is increasing evidence that activation of PPARγ
by TZDs could alter the transcription of hundreds of
genes, only part of which contribute to glycemic con-
trol. It is conceivable that some of the other altered
gene transcription cascades may lead to the develop-
ment of cardiovascular complications. In addition,
PPARγ-independent actions of TZDs have been sug-
gested as a result of drug binding to cellular proteins
different from PPARγ [4]. In this respect it might be
significant that rosiglitazone-induced myocardial hyper-
trophy, an early hallmark and important risk factor for
the development of heart failure [9], still occurs in
cardiomyocyte-specific PPARγ knock-out mice [10].
In the present study we have used a systems biology
approach for assessing similarities and differences be-
tween rosiglitazone and pioglitazone in gene expression
profiles in the heart of a mouse model that mimics sev-
eral of the characteristics of diabetes as observed in
humans treated with rosiglitazone or pioglitazone. Bio-
informatic analysis of expression profiles was used to
identify regulatory pathways and upstream regulators
that are influenced by the two TZD treatments. Similar-
ities in expression patterns between the two drugs may
reveal unknown mechanisms of action in addition to
PPARγ binding, and possible sources of shared effects.
Conversely, differences may reveal different regulatory
events leading to the increased cardiovascular risk that
may be unique to a specific glitazone. From the current
study several findings emerged that provide insights into
differential effects of rosiglitazone and pioglitazone
within the cardiovascular system, including implications
for compounding drug efficacy and cardiotoxicity.Methods
Animals
The study was approved by the animal Ethics Commit-
tee of TNO, the Netherlands, and animal handling was
performed according to the European directive on
Laboratory Animals (86/609/EEC). Male LDLr deficient
mice were bred in TNO facilities and housed in wire-topped Macrolon cages with a layer of sawdust as bed-
ding, and diets and water were provided ad libitum.
Study design and diets
The current study is part of a larger study, the design of
which has been described in detail elsewhere [11]. In short,
to induce characteristics of pre-diabetes, male LDLr defi-
cient mice (n = 33) received Western type High Fat diet
containing 24% (w/w) lard fat (Research diets D12541,
USA), further referred to as High-Fat (HF), diet for 9
weeks. Then, mice were subdivided into three experimental
groups and matched for plasma cholesterol and body
weight (t = 0). One group (n = 15 mice, control) continued
the HF-diet treatment, while the other two groups were fed
an HF-diet containing rosiglitazone (0.01% w/w; Avandia,
GSK) or pioglitazone (0.01% w/w; Actos, Takeda) for an
additional 7 weeks. The daily doses of rosiglitazone and pi-
oglitazone are 5.6 mg/kg body weight/day and 7.2 mg/kg
body weight, respectively. In parallel to these HF-diet
groups a separate control group was kept on chow for the
duration of the experiment and served as a reference con-
trol for aging. Throughout the experiment all experimental
diets were well tolerated and mice in the various treatment
groups consumed comparable amounts of calories.
Analysis of plasma glucose and insulin, and urinary
albumin levels
Plasma was obtained via tail vein bleeding after 5 hours of
fasting. Plasma glucose was quantified by the glucose hexo-
kinase method (Instruchemie, Delfzijl, The Netherlands)
and plasma insulin by ELISA (Ultrasensitive mouse insulin
ELISA, Mercodia, Uppsala, Sweden). To assess glomerular
barrier function, urinary albumin (Exocell Inc. Philadelphia,
PA, USA) and creatinine concentrations were determined
(Bethyl Laboratories Inc. Montgomery, TX, USA).
Atherosclerotic lesion analysis
At the end of the study, mice were euthanized to collect
hearts and aortas. Hearts were weighted and divided in
two parts. The apex of the heart was snap-frozen in liquid
nitrogen and stored at −80°C. The upper part was fixed in
formalin and embedded into paraffin to prepare serial
cross sections (5 μm-thick) throughout the entire aortic
root area for histological analysis [12]. Cross-sections were
stained with hematoxylin-phloxine-saffron (HPS) and ath-
erosclerosis was analysed blindly in 4 cross-sections of
each specimen (at intervals of 40 μm). An Olympus BX51
microscope and Cell^D software (Olympus, Zoeterwoude,
The Netherlands) were used for morphometric computer-
assisted analysis of lesion number and area.
Nucleic acid extraction and microarray analysis
Nuclear acid extraction was performed as described previ-
ously in detail [13]. Briefly, total RNA was extracted from
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group, 16 samples in total, with normalized glucose
levels at <13mM) using glass beads and RNAzol
(Campro Scientific, Veenendaal, The Netherlands). RNA
integrity was examined using the RNA 6000 Nano
Lab-on-a-Chip kit and a bioanalyzer 2100 (Agilent
Technologies, Amstelveen, The Netherlands). The Illu-
mina® TotalPrep™ RNA Amplification Kit (Ambion, art.
No.AM-IL1791) was used to synthesize biotin labeled
cRNA starting with 500 ng total RNA. The concentra-
tion of the labeled cRNA was measured using the
Nanodrop spectrophotometer. The amount of biotinyl-
ated cRNA which was hybridized onto the MouseRef-8
Expression BeadChip was 750 ng. Illumina’s Genomes-
tudio v1.1.1 software with the default settings advised
by Illumina was used for Gene Expression analysis. All
the quality control data of this BeadChip were within
specifications of the microarray service provider (Service
XS, Leiden, the Netherlands).
Microarray data analysis
The probe-level background subtracted expression values
were used as input for lumi package [14] of the R/Biocon-
ductor (http://www.bioconductor.org; http://www.r-project.
org) to perform quality control and a quantile normalization.
Unexpressed probes (p > 0.01 in all experiments) were
removed from further analysis, and 15725 probes remained
in the analysis. Differentially expressed probes were identi-
fied using the limma package of R/Bioconductor [15]. The
calculated P-values <0.01 were used as threshold for sig-
nificance in cardiac tissue. Selected differentially expressed
probes (DEPs) were used as an input for pathway analysis
through Ingenuity Pathway Analysis suite (www.ingenuity.
com, accessed 2013).
Upstream regulator analysis was performed using the
Ingenuity Pathway Analysis (IPA) software. This analysis
determines the activation state of transcription factors
based on the observed differential gene expression. This re-
sults in an overlap p-value and activation z-score for each
transcription factor in the IPA knowledgebase. The overlap
p-value indicates the significance of the overlap between
the known target genes of a transcription factor and the
differentially expressed genes measured in an experiment.
The activation z-score indicates activation (positive z-score)
or inhibition (negative z-score) of a particular transcription
factor. An activation z-score <-2 or >2 indicates significant
activation or inhibition of a pathway or process.
cDNA synthesis and quantitative real-time polymerase
chain reaction
cDNA was synthesized from heart tissue RNA from
mice in the HF + Rosi and HF + Pio groups with similar,
i.e. normalized glucose levels. One microgram of total
RNA was used for the high capacity RNA to cDNA kit(4387406, Applied Biosystems). Real time PCR was
performed in triplicate on a Fast 7500 using the Taq-
Man gene expression assays (Applied Biosystems). Specific
probes were applied to detect transcripts for B-type natri-
uretic peptide (Bnp;Mm01255770_g1 ) and A-type natri-
uretic peptide (Anp;Mm01255747_g1). The probes solute
carrier family 27 (fatty acid transporter), member 1
(Slc27a1,Fatp; Mm00449511_M1), uncoupling protein 3
(Ucp3; Mm00494077_M1), Acyl-CoA dehydrogenase, very
long chain (Acadvl Mm00444293_M1), and carnitine
palmitoyltransferase 1b (Cpt1b; Mm00487200_M1) were
applied to validate microarray results. All signals were
compared to glyceraldehyde 3-phosphate dehydrogen-
ase (Gapdh;4308313), hypoxanthine-guanine phosphor-
ibosyltransferase (Hprt;Mm00446968_m1) and peptidylprolyl
isomerase F (Ppif;Mm00506384_m1) as housekeeping genes.Statistics
All efficacy data are presented as mean ± standard devi-
ation (SD). Data were analyzed using One-Way analysis of
variance (ANOVA) and least significant difference (LSD)
post hoc test unless stated otherwise. In all tests per-
formed, the null hypothesis was rejected at the level of 5%
probability (α = 0.05).Results
Metabolic parameters
LDLr−/− mice fed an HF-diet over a 16-week period
showed a significantly higher increase in body weight
(15.8 ± 4.6 g) relative to mice on standard chow (3.2 ±
1.6 g; P < 0.001). The body weight gains of mice fed HF +
Rosiglitazone (HF + Rosi) or HF + Pioglitazone (HF + Pio)
tended to be even higher than those of HF fed mice (+14%
and +10%, respectively; not statistically significant).
HF-diet significantly increased plasma fasting glucose
(15.0 ± 1.9 mM; P < 0.001; Figure 1A) compared to chow
diet (11.3 ± 1.6 mM). HF + Rosi and HF + Pio treatment
significantly reduced fasting glucose levels to 10.6 ± 0.7
mM (P < 0.01) and 12.2 ± 2.1 mM (P < 0.01), respectively.
Fasting plasma insulin levels significantly increased with
HF-diet to 4.3 ± 3.3 ng/ml vs. 0.7 ± 0.5 ng/ml with chow
diet (P < 0.001; Figure 1B). HF + Rosi (1.4 ± 0.6 ng/ml; P <
0.01) and HF + Pio (2.7 ± 1.8 ng/ml; P = 0.09) treatment
reduced fasting insulin levels. Urinary albumin/creatinine
ratio, an indication for microalbuminuria, showed a 2.8-
fold increase (186 ± 29 μg/mg; P < 0.05; Figure 1C) with
HF-diet compared to chow diet (65 ± 19 μg/mg). Both
HF + Rosi (116 ± 39 μg/mg; P < 0.05) and HF + Pio (143 ±
25 μg/mg; P < 0.05) significantly reduced the HF-diet-
induced increase in albumin/creatinine ratio. In all,
these data demonstrate that both HF + Rosi and HF +










Figure 1 Effect of drug treatment on metabolic parameters in LDLr−/−mice fed a chow diet or an HF-diet supplemented with rosiglitazone
(HF + Rosi) or pioglitazone (HF + Pio). Fasting plasma levels of glucose (A) and insulin (B), and albumin/creatinin ratio in urine (C). Values are
mean ± SD. # indicates statistical significance P < 0.05 compared to chow, *indicates statistical significance P < 0.05 compared to HF-diet.
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HF-diet increased heart weight only slightly (167 ± 30 mg)
compared to chow (151 ± 15 mg; not significant). Treat-
ment with rosiglitazone significantly increased heart
weight relative to HF (211 ± 29 mg; P < 0.05; Figure 2A).
Also, the heart-to-body weight ratio (HW/BW) of HF +
Rosi was increased compared with HF-diet (0.48% ±
0.06% vs. 0.39% ± 0.06%; P < 0.05). In contrast, pioglita-
zone did not affect heart weight (172 ± 34 mg) or HW/
BW ratio (0.40% ± 0.06%) compared with HF. The in-
creased heart weight in the HF + Rosi group was ac-
companied by an upregulation of the fetal/stress genes
B-type natriuretic peptide (Bnp) (2.43 ± 0.33; P < 0.001;
Figure 2B) and atrial natriuretic peptide (Anp) (1.62 ±0.44; P < 0.01; Figure 2C), relative to the HF group
(Bnp, 1.0 ± 0.14; Anp, 1.0 ± 0.14). Augmented expres-
sion of Bnp and Anp indicates pathological cardiac
growth of the heart, which is an important and inde-
pendent risk factor for cardiovascular diseases. Notably,
Bnp (1.19 ± 0.41) and Anp (0.88 ± 0.36) transcript levels
were not significantly altered with pioglitazone. Another
common cause of cardiovascular disease is the develop-
ment of atherosclerosis. Histological analysis of the aortic
root showed that 16 weeks of HF-diet treatment alone
mildly increased atherosclerosis development in LDLr-
deficient mice (23,800 ± 4,460 μm2) compared with chow-
fed mice (4,300 ± 850 μm2; P < 0.01). Rosiglitazone treat-









Figure 2 Effect of drug treatment on cardiac parameters of LDLr-/- mice. Heart weight (A), gene expression of cardiac stress marker Bnp (B),
and Anp (C) assessed by RT-PCR, and quantitative analysis of atherosclerotic lesions in the aortic root area (D). Values are mean ± SEM. # indicates
statistical significance P < 0.05 compared to chow, *indicates statistical significance P < 0.05 compared to HF-diet.
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while HF + Pio showed no significant differences (34300 ±
8830 μm2). The question then arises what mechanistic
processes could underlie these cardiac adverse effects
of rosiglitazone. To address this question a genome-
wide gene expression analysis of selected heart tissue
samples was carried out.
Genome-wide transcriptome analysis
To elucidate which gene regulatory processes are modu-
lated in the hearts of HF + Rosi and HF + Rio treated mice,
transcriptome analysis of heart tissue was performed. Ofnote, heart tissue was used from mice that showed nor-
malized plasma glucose levels (viz. below 13 mM) upon
rosiglitazone or pioglitazone treatment (Figure 3A).
Genes that were differentially expressed in the HF + Rosi
(Additional file 1: Table S1) and HF + Pio (Additional
file 2: Table S2) treatment groups relative to the HF-
group were used for analysis of biological processes.
The majority of the affected genes were modulated by
rosiglitazone (700 genes compared to 345 genes with
pioglitazone), and 76 genes were affected by both com-
pounds (Venn-diagram; Figure 3B). Notably, only 39 genes





















Figure 3 Cardiac transcriptome analysis. Relationship between fasting plasma glucose concentration and heart weight (A), Venn-diagrams
showing overlap in the total number of differentially expressed genes (B) and PPARγ target genes (C) in cardiac tissue in HF + Rosi and HF + Pio
groups relative to HF-diet control group (P < 0.01). Graphical representation (D) of significantly enriched Biological Processes in HF + Rosi and HF +
Pio treatment groups relative to HF-diet control group. Bars display a selection of significantly enriched biological processes (−log10 (p-value))
modulated by HF + Rosi (dark bars) or HF + Pio (light bars).
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(Figure 3C). Together this shows that treatment with rosi-
glitazone, and to a lesser extent pioglitazone, is accompan-
ied by substantial gene expression changes in the heart,
but most of these changes are not direct related to PPARγ.
To get insight into potential changes of biological pro-
cesses geneset enrichment analysis was performed.
Sixty-seven (67) processes were significantly enriched by
rosiglitazone and 49 processes by pioglitazone (Thresh-
old p-value 0.001; Additional file 3: Table S3). The
process “Carbohydrate metabolism” was affected by both
drugs and to a comparable extent. All other processes
including “Lipid Metabolism” and “Inflammatory Re-
sponse” were affected by rosiglitazone to greater extent
than by pioglitazone (Figure 3D). Of note, the process
“Energy Production” was affected by rosiglitazone only.
To further delineate the molecular processes that
could underlie the adverse cardiac effects of rosiglita-
zone, we evaluated the rosiglitazone-specific genes of the
Venn-diagram. In silico prediction of transcription factor
activity based on the expression changes of known target
genes revealed reduced activity of PPARα (p-value
3.4E-10; z-score −3.1) and PGC1α (p-value 1.1E-03;
z-score −2.1) upon rosiglitazone treatment and an effect
on target genes in the heart, including UCP3, FATP1,
CPT-1, and ACADVL (Additional file 4: Table S4). The
specific findings on the target genes from the trans-
criptome analysis are validated using RT-PCR method
(Figure 4A-D). Functional geneset enrichment analysis of
the dataset shows that these rosiglitazone-specific effects,
involving PPARα and/or PGC1α-controlled genes, do at
least partly explain the typical effects on the biological
processes: Lipid Metabolism, Fatty Acid Metabolism and
Energy Production (Venn diagrams; Figure 5A and B).
Overall the effects of rosiglitazone on PPARα and PGC1α
regulated genes indicate a strong down regulation of genes
involved in Lipid Metabolism (Figure 5C) and Energy Pro-
duction (Figure 5D) in the heart which might contribute
to the observed pathological hypertrophy because such
effects were not observed with pioglitazone.
Discussion
The discrepancy in cardiovascular risk between patients
taking rosiglitazone or pioglitazone and lack of insight
into the underlying causes elicited the present study in
mice [16,17]. Mouse heart tissue was used, since this
allowed a comprehensive analysis of similarities and dif-
ferences between rosiglitazone and pioglitazone. Bio-
informatic analysis of the gene expression data identified
regulatory pathways and upstream regulators that are
specifically influenced by rosiglitazone.
In a high-fat diet-inducible model of combined hyper-
glycemia and cardiovascular disease we found that rosi-
glitazone and pioglitazone are effective glucose loweringdrugs which markedly improved systemic markers of
glucose homeostasis, fasting plasma glucose and insulin,
and the urinary excretion of albumin. These findings are
in line with observations made in humans [18,19] and
other rodent models [20,21]. Importantly, only rosiglita-
zone treatment caused cardiac hypertrophy, defined as a
significant increase in heart weight, and tended to in-
crease atherosclerosis in the aortic root area. To our
knowledge the disparate capacity of rosiglitazone and pi-
oglitazone to induce cardiac hypertrophy was never
studied before in a diet-induced mouse model. In gen-
eral, two forms of cardiac hypertrophy can be distin-
guished, physiological and pathological hypertrophy. The
latter is a significant independent risk factor for cardio-
vascular mortality and morbidity ([22], and references
therein). Our study demonstrate that validated markers
for pathological cardiac hypertrophy, ANP and BNP
[23], were elevated by rosiglitazone but not by pioglita-
zone. This demonstrates that only rosiglitazone induced
pathological cardiac hypertrophy in these mice within
the study period of 7 weeks. Consistent with our obser-
vation in mice, rosiglitazone treatment also increased
BNP plasma levels in T2DM patients without previous
signs of cardiovascular disease [24], while pioglitazone
did not have an effect on BNP levels [25].
Microarray technology is a powerful technique to analyze
the effect of interventions on thousands of genes and across
pathways [13]. Transcriptome analysis of the heart tissue
revealed that, under conditions at which rosiglitazone and
pioglitazone showed comparable hypoglycemic effects, 624
genes were significantly and differently altered by rosiglita-
zone. Only 31 of these are reportedly controlled by PPARγ.
Furthermore, our analysis demonstrates that 354 genes are
affected by pioglitazone, only 8 genes of which are target of
PPARγ and all are in common with rosiglitazone. This im-
plies, that in case the pathological cardiac hypertrophy is
induced through a PPARγ-dependent mechanism, it could
be caused by 31 rosiglitazone-modulated genes. However,
the role of PPARγ in the development of pathological car-
diac hypertrophy and in mediating the effect of rosiglita-
zone thereupon is not entirely clear yet. Several studies
suggest that PPARγ is protective, as mice lacking PPARγ
in the heart developed cardiac hypertrophy and dys-
function [26,27] and treatment with a PPARγ agonist
reduced cardiac remodeling and fibrosis in a rat model
of hypertension [27]. Yet, cardiac-specific over-expression
of PPARγ in mice also resulted in cardiac dysfunction
[28]. Another study demonstrated that transgenic mice
with enhanced PPARγ activity developed concentric
hypertrophy which progressed to dilated cardiomyopathy
[29]. On the other hand, a study using cardiomyocyte-
specific PPARγ knock-out mice indicated that rosiglitazone
can promote the development of myocardial hypertrophy






Figure 4 Effect of drug treatment on gene expression changes. Relative expression of genes Ucp3 (A), Fatp1 (B), Cpt1b (C), and Acadvl (D)
assessed by RT-PCR. Values are mean ± SD. *indicates statistical significance P < 0.05 compared to HF-diet.
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primarily met by the β-oxidation of fatty acids, to main-
tain the continuous contractile activity [30]. There isincreasing evidence that a shift in cardiac energy metabol-
ism towards decreased fatty acid oxidation and increased












Figure 5 PPARα and PGC1α target gene regulation. Venn-diagrams displaying the number of target genes affected by nuclear transcription
factor PPARα (A) and PGC1α (B). PPARα (C) and PGC1α (D) target genes that are significantly upregulated (red) or downregulated (green) by
rosiglitazone relative to HF-diet control (P < 0.01).
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tome analysis of the heart revealed that such a switch from
fatty acid to glycolytic metabolism may also underlie the
rosiglitazone-associated pathological hypertrophic cardiac
phenotype in the current study. Rosiglitazone, but not pio-
glitazone, down regulated PPARα and PGC1α target genes.
In PPARα−/− mice, cardiac hypertrophy is induced [31],
and also in mice lacking PGC-1α, cardiac dysfunction be-
comes evident [32]. Functional enrichment analysis of the
genes specifically affected by rosiglitazone indicates that
the down regulated genes are related to biological pro-
cesses ‘Lipid Metabolism’ and ‘Energy Production’ and
included CPT1, VLCAD, and LCAD. Inhibition of CPT1
in cardiac tissue has been demonstrated to induce cardiac
hypertrophy [33,34]. Similarly, cardiac hypertrophy was
found in mice deficient in VLCAD or LCAD [35]. Further
evidence for a putative role of PPARα in cardiac hyper-
trophy comes from studies on fibroblast growth factor 21
(FGF21), which is expressed in and released by cardio-
myocytes through a PPARα − dependent mechanism [36].
Deficiency of FGF21 in the heart was demonstrated toinduce of cardiac hypertrophy markers and reduce fatty
acid oxidation [37].
Conclusion
The mouse model of rosiglitazone-induced cardiac patho-
logical hypertrophy combined with bioinformatics ana-
lysis of the transcriptome of the heart offers important
insights into the pathophysiology of adverse cardiac
hypertrophy. In particular, we uncovered a shift in car-
diac energy metabolism from fatty acid oxidation to-
ward increased glucose utilization and the roles of
relevant PPARα and PGC1α target genes therein. These
findings are also relevant for improving future drug ef-
ficacy void of cardiotoxicity.
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